BFM
FATE icon

Boothbay Fund Management’s Fate Therapeutics FATE Stock Holding History

Boothbay Fund Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-40
Closed -$364K – 1622
2020
Q4 		$364K Buy
+40
New +$2.48K 0.01% 872
2018
Q2 		– Sell
-435
Closed -$425K – 787
2018
Q1 		$425K Buy
+435
New +$4.17K 0.05% 367

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Boothbay Fund Management's FATE Position: Q1 2025 in Review

Boothbay Fund Management sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 10,666 shares — an estimated $17.6K sold.

Boothbay Fund Management first reported a position in FATE in Q1 2019 and held it in 2 quarters. The position peaked at $647K in Q1 2019. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • Boothbay Fund Management reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 10,666 Fate Therapeutics shares in Q1 2025, an estimated $17.6K.
  • Boothbay Fund Management first reported a position in Fate Therapeutics in Q1 2019 and held it in 2 quarters.
  • Boothbay Fund Management's Fate Therapeutics position peaked at $647K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.